Medyria closes series B round and receives approval for first-in-man clinical trial


Medtech startup Medyria spcialising in cardiovascular catheter navigation and sensing has successfully closed its series B round at CHF 3.7 Million with a contribution of CHF 1.28 from The medtech startup also announces receipt of approval for first-in-man clinical trials.


With the funds from the B round closing, Medyria is now set for their first-in-man clinical trials for its catheter positioning system, thanks to the green-light from the German Federal Institute for Drugs and Medical Devices (BfArM).

“We always believed in Medyria’s highly relevant technology in the fast-growing market of endovascular surgery and recognized its potential already in 2014 when we conducted a first investment round and added it to our portfolio”, says Michael Blank, Investment Manager at “We are very happy and proud that we could enable our investors to participate in two financing rounds before the first human trials and we look forward to continue supporting Medyria along its journey.”

Medyria has developed a catheter positioning system with the potential to significantly reduce the use of x-ray and contrast dye. Today, such interventions are visualized using x-ray and contrast-dye, both of which can lead to severe health complications. In fact, 41% of patients are at risk of developing kidney damage or allergic reactions to the dye. Medyria’s technology significantly reduces patient risks and cuts costs by shortening hospital stays and eliminating toxic contrast dye complications. Numerous project milestones have already been reached, including successful animal trials as well as product verification and validation. Medyria will begin the human trials in the coming weeks.

(Press release)